Renibus Therapeutics has completed enrollment of 423 patients across 40 sites in the US and Canada for its Phase 3 PROTECT trial evaluating RBT-1, with topline results expected in Q3 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.